Literature DB >> 15456947

Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy.

Kadri Altundag1, Sercan Aksoy, Ibrahim Gullu, Ozden Altundag, Enis Ozyar, Suayib Yalcin, Mustafa Cengiz, Fadil Akyol.   

Abstract

This study evaluated the efficacy and toxicity of ifosfamide and doxorubicin chemotherapy regimen in Turkish patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) previously treated with platinum-based chemotherapy. Twenty-one patients with recurrent or metastatic NPC previously treated with platinum-based chemotherapy as adjuvant or palliative treatments who received ifosfamide 2500 mg/m(2) d 1-3, mesna 2500 mg/m(2) d 1-3, doxorubicin 60 mg/m(2) d 1, repeated every 21 d was retrospectively analyzed. Patients received a median number of three cycles of ifosfamide-doxorubicin (range: 1-6). Seven patients (33.3%) achieved partial response and no patient achieved complete response. Six (28.5%) had stable disease, whereas three (18.75%) had progressive disease. The median time to progression was 7.0 mo. Ifosfamide-doxorubicin regimen is an effective salvage regimen in patients with recurrent and metastatic NPC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456947     DOI: 10.1385/MO:21:3:211

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  18 in total

1.  A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.

Authors:  Daniel T T Chua; Jonathan S T Sham; Gordon K H Au
Journal:  Oral Oncol       Date:  2003-06       Impact factor: 5.337

2.  Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure.

Authors:  A W Lee; Y F Poon; W Foo; S C Law; F K Cheung; D K Chan; S Y Tung; M Thaw; J H Ho
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

3.  Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.

Authors:  A Taamma; A Fandi; N Azli; P Wibault; N Chouaki; A Hasbini; C Couteau; J P Armand; E Cvitkovic
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

Review 4.  Nasopharyngeal cancer: epidemiology, staging, and treatment.

Authors:  A Fandi; M Altun; N Azli; J P Armand; E Cvitkovic
Journal:  Semin Oncol       Date:  1994-06       Impact factor: 4.929

5.  Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type.

Authors:  K F Foo; E H Tan; S S Leong; J T S Wee; T Tan; K W Fong; L Koh; B C Tai; L G Lian; D Machin
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

6.  A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma.

Authors:  W Yeo; T W Leung; A T Chan; S K Chiu; P Yu; T S Mok; P J Johnson
Journal:  Eur J Cancer       Date:  1998-12       Impact factor: 9.162

7.  Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.

Authors:  A Hasbini; R Mahjoubi; A Fandi; N Chouaki; A Taamma; P Lianes; H Cortès-Funes; S Alonso; J P Armand; E Cvitkovic; E Raymond
Journal:  Ann Oncol       Date:  1999-04       Impact factor: 32.976

8.  A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.

Authors:  J S McCarthy; I F Tannock; P Degendorfer; T Panzarella; M Furlan; L L Siu
Journal:  Oral Oncol       Date:  2002-10       Impact factor: 5.337

9.  High-dose epirubicin and cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma.

Authors:  H Onat; M Basaran; M Esassolak; S E Bavbek; Y Anacak; E Kaytan; M Altun; A Haydaroglu
Journal:  Clin Oncol (R Coll Radiol)       Date:  2002-12       Impact factor: 4.126

10.  Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx.

Authors:  L L Siu; P M Czaykowski; I F Tannock
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

View more
  5 in total

Review 1.  Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.

Authors:  Tao Xu; J Tang; M Gu; L Liu; W Wei; H Yang
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

2.  An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma.

Authors:  Sik-Kwan Chan; Brian O'Sullivan; Shao Hui Huang; Tin-Ching Chau; Ka-On Lam; Sum-Yin Chan; Chi-Chung Tong; Varut Vardhanabhuti; Dora Lai-Wan Kwong; Chor-Yi Ng; To-Wai Leung; Mai-Yee Luk; Anne Wing-Mui Lee; Horace Cheuk-Wai Choi; Victor Ho-Fun Lee
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.575

Review 3.  Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review.

Authors:  A Prawira; S F Oosting; T W Chen; K A Delos Santos; R Saluja; L Wang; L L Siu; K K W Chan; A R Hansen
Journal:  Br J Cancer       Date:  2017-10-24       Impact factor: 7.640

4.  Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.

Authors:  Victor H F Lee; Dora L W Kwong; Ka-On Lam; Yu-Ching Lai; Yun Li; Chi-Chung Tong; Patty P Y Ho; Wing-Lok Chan; Lai-San Wong; Dennis K C Leung; Sum-Yin Chan; Fong-Ting Chan; To-Wai Leung; Anne W M Lee
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

5.  HOTAIR mediates cisplatin resistance in nasopharyngeal carcinoma by regulating miR-106a-5p/SOX4 axis.

Authors:  Wei Cao; Yi Sun; Long Liu; Junwei Yu; Jiabiao Ji; Yatang Wang; Jianming Yang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.